Skip to main content

Psoriatic arthritis

      RT @philipcrobinson: Replacing radiographic sacroiliitis with MRI structural damage doesn't change the classifciation of
      4 years 6 months ago
      Replacing radiographic sacroiliitis with MRI structural damage doesn't change the classifciation of axSpA signifciantly @RheumNow #EULAR2020 Abstract SAT0384 https://t.co/MTTf4fHjYT
      RT @philipcrobinson: Preliminary definition of a +MRI for struc lesions in the SIJs in axSpA: Erosion in ≥2 consec sli
      4 years 6 months ago
      Preliminary definition of a +MRI for struc lesions in the SIJs in axSpA: Erosion in ≥2 consec slices or in ≥3 SIJ quad and fat lesion w depth >1cm in ≥1 SIJ quad are high priority for def an MRI struc lesion of axSpA. Abs OP0079 #EULAR2020 @RheumNow https://t.co/9RlSOUviJQ https://t.co/l4XiQDj8e4
      RT @philipcrobinson: Secukinumab in nr-axSpA, in a mostly biologic naive cohort was effective: ASAS40 response of ~42%,
      4 years 6 months ago
      Secukinumab in nr-axSpA, in a mostly biologic naive cohort was effective: ASAS40 response of ~42%, data from the Phase III prevent trial Abstract OP0106 #EULAR2020 @rheumnow https://t.co/KATpGJs2y9 https://t.co/zeBFS2pMl0
      RT @DrPetryna: #Eular2020 #op0224 filgotinib successfully reduces levels of circulating biomarkers in PsA suggestive of
      4 years 6 months ago
      #Eular2020 #op0224 filgotinib successfully reduces levels of circulating biomarkers in PsA suggestive of clinical efficacy: CRP&SAA >50%, IL6, CXCL10&IL23 >25%. Also decreased ICAM1,VCAM1, MMP1&SC1M @RheumNow
      RT @KDAO2011: #EULAR2020 ABST#OP0014 Plenary session: Secukinumab and etanercept do NOT work for anterior uveitis in SpA
      4 years 6 months ago
      #EULAR2020 ABST#OP0014 Plenary session: Secukinumab and etanercept do NOT work for anterior uveitis in SpA based on Swedish Rheum Quality Registry of > 2600 patients @rheumnow https://t.co/2kJ3b4JObq
      RT @KDAO2011: #EULAR2020 Abstr#LB001 Coming soon...another indication for @Rinvoq? Favorable response in phase III trial
      4 years 6 months ago
      #EULAR2020 Abstr#LB001 Coming soon...another indication for @Rinvoq? Favorable response in phase III trial of upadacitinib vs. ADA vs. PCB for PsA (SELECT-PsA-1) @abbvie @rheumnow https://t.co/0udmPlR2pQ
      RT @KDAO2011: #EULAR2020 Dr. Kimme Hyrich reviews the EULAR #COVID19 Registry "Most individuals with rheumatic diseases
      4 years 6 months ago
      #EULAR2020 Dr. Kimme Hyrich reviews the EULAR #COVID19 Registry "Most individuals with rheumatic diseases receiving immunosuppressive therapies recover from COVID19" @rheumnow https://t.co/EdVLUMyHhF
      RT @uptoTate: A study worth remembering. Pts with FM-PsA had statistically higher PsA dz activity in subjective measures
      4 years 6 months ago
      A study worth remembering. Pts with FM-PsA had statistically higher PsA dz activity in subjective measures ONLY, not in objective measures. Make sure you take time to fully treat your patients and give them tools for FM as well as PsA. #EULAR2020 @RheumNow #AB0731 https://t.co/e3JkEmq3EZ
      RT @uptoTate: SELECT-PSA-2 results: UPA15 & UPA30 showed improvement across PsA domains vs PBO through Wk 24. No ne
      4 years 6 months ago
      SELECT-PSA-2 results: UPA15 & UPA30 showed improvement across PsA domains vs PBO through Wk 24. No new safety signals were identified. Check out abstract #OP0223 for the MDA/ACR50/ACR70 responses. #EULAR2020 @RheumNow https://t.co/UAx2tkKSZI
      RT @uptoTate: Do you use different medications for different PsA domains? Teach me how you practice! #EULAR2020 @RheumN
      4 years 6 months ago
      Do you use different medications for different PsA domains? Teach me how you practice! #EULAR2020 @RheumNow
      ×